Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats.

Yoshimizu T, Shimazaki T, Ito A, Chaki S.

Psychopharmacology (Berl). 2006 Jul;186(4):587-93. Epub 2006 Apr 13.

PMID:
16612616
2.

On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039.

Pałucha-Poniewiera A, Wierońska JM, Brański P, Stachowicz K, Chaki S, Pilc A.

Psychopharmacology (Berl). 2010 Dec;212(4):523-35. doi: 10.1007/s00213-010-1978-5. Epub 2010 Aug 12.

3.

MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity.

Chaki S, Yoshikawa R, Hirota S, Shimazaki T, Maeda M, Kawashima N, Yoshimizu T, Yasuhara A, Sakagami K, Okuyama S, Nakanishi S, Nakazato A.

Neuropharmacology. 2004 Mar;46(4):457-67.

PMID:
14975669
4.

AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist.

Karasawa J, Shimazaki T, Kawashima N, Chaki S.

Brain Res. 2005 Apr 25;1042(1):92-8.

PMID:
15823257
5.

Anxiolytic-like activity of MGS0039, a selective group II mGlu receptor antagonist, is serotonin- and GABA-dependent.

Stachowicz K, Wierońska J, Domin H, Chaki S, Pilc A.

Pharmacol Rep. 2011;63(4):880-7.

6.
7.

Prodrugs of 3-(3,4-dichlorobenzyloxy)-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (MGS0039): a potent and orally active group II mGluR antagonist with antidepressant-like potential.

Yasuhara A, Nakamura M, Sakagami K, Shimazaki T, Yoshikawa R, Chaki S, Ohta H, Nakazato A.

Bioorg Med Chem. 2006 Jun 15;14(12):4193-207. Epub 2006 Feb 17.

PMID:
16487713
8.

A metabotropic glutamate 2/3 receptor antagonist, MGS0039, increases extracellular dopamine levels in the nucleus accumbens shell.

Karasawa J, Yoshimizu T, Chaki S.

Neurosci Lett. 2006 Jan 30;393(2-3):127-30. Epub 2005 Oct 17.

PMID:
16233956
9.

Involvement of the mammalian target of rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists.

Koike H, Iijima M, Chaki S.

Neuropharmacology. 2011 Dec;61(8):1419-23. doi: 10.1016/j.neuropharm.2011.08.034. Epub 2011 Aug 31.

PMID:
21903115
10.

Neuropharmacological profiles of antagonists of group II metabotropic glutamate receptors.

Kawashima N, Karasawa J, Shimazaki T, Chaki S, Okuyama S, Yasuhara A, Nakazato A.

Neurosci Lett. 2005 Apr 22;378(3):131-4. Epub 2005 Jan 5.

PMID:
15781145
12.
13.

Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition.

Schlumberger C, Schäfer D, Barberi C, Morè L, Nagel J, Pietraszek M, Schmidt WJ, Danysz W.

Behav Pharmacol. 2009 Feb;20(1):56-66. doi: 10.1097/FBP.0b013e3283242f57.

PMID:
19179851
14.

Synthesis, in vitro pharmacology, and structure-activity relationships of 2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as mGluR2 antagonists.

Yasuhara A, Sakagami K, Yoshikawa R, Chaki S, Nakamura M, Nakazato A.

Bioorg Med Chem. 2006 May 15;14(10):3405-20. Epub 2006 Jan 20.

PMID:
16431115
16.

Synthesis, SARs, and pharmacological characterization of 2-amino-3 or 6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent, selective, and orally active group II metabotropic glutamate receptor agonists.

Nakazato A, Kumagai T, Sakagami K, Yoshikawa R, Suzuki Y, Chaki S, Ito H, Taguchi T, Nakanishi S, Okuyama S.

J Med Chem. 2000 Dec 14;43(25):4893-909.

PMID:
11123999
17.

Blockade of the metabotropic glutamate 2/3 receptors enhances social memory via the AMPA receptor in rats.

Shimazaki T, Kaku A, Chaki S.

Eur J Pharmacol. 2007 Dec 1;575(1-3):94-7. Epub 2007 Aug 14.

PMID:
17727837
19.

In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders.

Rorick-Kehn LM, Johnson BG, Knitowski KM, Salhoff CR, Witkin JM, Perry KW, Griffey KI, Tizzano JP, Monn JA, McKinzie DL, Schoepp DD.

Psychopharmacology (Berl). 2007 Jul;193(1):121-36. Epub 2007 Mar 24.

PMID:
17384937
20.

Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors.

Helton DR, Tizzano JP, Monn JA, Schoepp DD, Kallman MJ.

J Pharmacol Exp Ther. 1998 Feb;284(2):651-60.

Supplemental Content

Support Center